# ASKB589 in Combination With CAPOX and PD-1 Inhibitors in Patients With Advanced, and Unresectable G/GEJ Cancer.

Source: https://onco.cc/trials/nct05632939/  
OnCo record `nct05632939` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of CAPOX, Sintilimab, Tislelizumab in oesophageal cancer, run by AskGene Pharma, Inc., active and no longer recruiting.

## Summary

ASKB589 in Combination With CAPOX and PD-1 Inhibitors in Patients With Advanced, and Unresectable G/GEJ Cancer. is a phase 1/2 interventional study registered as NCT05632939 by AskGene Pharma, Inc., with 62 participants enrolled, started 2023-02-21 and due to reach its primary completion in 2025-10-31. Interventions recorded: ASKB589 +CAPOX+Sintilimab/Tislelizumab. Conditions listed: Gastric Cancer, Gastroesophageal Cancer (GC). No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05632939
- Phase: 1/2
- Setting: A 1/2 Phase Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ASKB589 in Combination With CAPOX and PD-1 Inhibitors in Patients With Advanced, and Unresectable Gastric/Esophagogastric Junction Cancer.
- Sponsor: AskGene Pharma, Inc.
- Enrolled: 62

## Sources

- ClinicalTrials.gov NCT05632939: https://clinicaltrials.gov/study/NCT05632939

## Connected records

- cancers: [Oesophageal cancer](https://onco.cc/cancers/esophageal/)
- drugs: [CAPOX (capecitabine, oxaliplatin)](https://onco.cc/drugs/capox/), [Sintilimab](https://onco.cc/drugs/sintilimab/), [Tislelizumab](https://onco.cc/drugs/tislelizumab/)
- companies: [AskGene Pharma](https://onco.cc/companies/askgene-pharma/)

---
JSON: https://onco.cc/api/v1/entities/nct05632939.json